Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +0.75% | -1.47% | +8.06% |
04-23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
04-16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Evolution of the average Target Price on Akebia Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Akebia Therapeutics, Inc.
HC Wainwright | |
Piper Sandler | |
Mizuho Securities | |
Needham & Co. | |
BTIG | |
Cantor Fitzgerald | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- AKBA Stock
- Consensus Akebia Therapeutics, Inc.